Mike Schwartz

Company: Sepul Bio

Job title: Chief Operating Officer

Bio:

Mike joined Sepul Bio in 2023 as the Chief Operating Officer. He brings over 25 years of experience in different aspects of drug development including Project Leadership, Project Management, Clinical, Clinical Operations, Patient Advocacy and Regulatory. Prior to joining Sepul Bio, Mike worked as VP, Global Project Leader & Head Portfolio and Project Management at ProQR Therapeutics and was actively involved in developing treatments for inherited retinal eye diseases such as Leber congenital amaurosis 10 and Usher syndrome. Prior to ProQR, Mike spent over 15 years at GlaxoSmithKline Pharmaceuticals, focusing mainly in the Ophthalmology space. Mike has been a consultant for multiple Ophthalmology Biotech companies in roles such as CEO advisor, project leadership and clinical development. He is a biopharmaceutical executive with extensive multi-disciplinary experience and a science-centric approach to R&D program strategy and execution. He has a strong track record in leading large teams through project management, portfolio management, clinical development strategy, clinical operations, therapeutic area strategic planning and organizational development. Mike holds a Master’s Degree in Pharmaceutical Sciences with an Executive Pharmaceutical Marketing MBA.

Seminars:

Advancing mRNA Therapies in Rare Ophthalmic Disorders: Lessons from Clinical Development 11:00 am

Differentiate mRNA therapies from DNA-based gene therapies, highlighting unique opportunities and challenges in ocular indications Share lessons learned from rare disease trial execution, including patient population considerations and regulatory navigation Explore the role of novel and alternative endpoints in inherited retinal disorder studies to better capture efficacyRead more

day: Conference Day Two